AU2019315327B2 - Pegylated tetanus neurotoxins and treatment of hypotonia - Google Patents

Pegylated tetanus neurotoxins and treatment of hypotonia Download PDF

Info

Publication number
AU2019315327B2
AU2019315327B2 AU2019315327A AU2019315327A AU2019315327B2 AU 2019315327 B2 AU2019315327 B2 AU 2019315327B2 AU 2019315327 A AU2019315327 A AU 2019315327A AU 2019315327 A AU2019315327 A AU 2019315327A AU 2019315327 B2 AU2019315327 B2 AU 2019315327B2
Authority
AU
Australia
Prior art keywords
tent
peg
pegylated
seq
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019315327A
Other languages
English (en)
Other versions
AU2019315327A1 (en
Inventor
Peter COLOE
Russell CONDUIT
Thomas Mclean
Luke NORBURY
Anthony Sasse
Peter SMOOKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snoretox Pty Ltd
Original Assignee
Snoretox Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018902779A external-priority patent/AU2018902779A0/en
Application filed by Snoretox Pty Ltd filed Critical Snoretox Pty Ltd
Publication of AU2019315327A1 publication Critical patent/AU2019315327A1/en
Application granted granted Critical
Publication of AU2019315327B2 publication Critical patent/AU2019315327B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
AU2019315327A 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia Active AU2019315327B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018902779 2018-07-31
AU2018902779A AU2018902779A0 (en) 2018-07-31 Composition and method
PCT/AU2019/050793 WO2020024002A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Publications (2)

Publication Number Publication Date
AU2019315327A1 AU2019315327A1 (en) 2021-02-11
AU2019315327B2 true AU2019315327B2 (en) 2024-05-09

Family

ID=69230503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019315327A Active AU2019315327B2 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Country Status (12)

Country Link
US (1) US20210353724A1 (https=)
EP (2) EP4134133A1 (https=)
JP (3) JP2021533201A (https=)
KR (1) KR20210040407A (https=)
CN (2) CN120661638A (https=)
AU (1) AU2019315327B2 (https=)
BR (1) BR112021001520A2 (https=)
CA (2) CA3167665A1 (https=)
MX (1) MX2021001181A (https=)
NZ (1) NZ772266A (https=)
SG (1) SG11202100646SA (https=)
WO (1) WO2020024002A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240268895A1 (en) 2023-02-15 2024-08-15 Canon Medical Systems Corporation X-ray diagnostic apparatus, x-ray diagnostic system, and x-ray diagnostic method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003200441B2 (en) * 1998-04-29 2006-07-06 Allergan, Inc. Compositions and methods for modulating neural sprouting
GB9914861D0 (en) * 1999-06-25 1999-08-25 Imperial College Tetanus toxin polypeptides
WO2002000172A2 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US20020197278A1 (en) * 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
WO2008024879A1 (en) * 2006-08-25 2008-02-28 University Of Maryland, Baltimore Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment
KR101818777B1 (ko) * 2009-04-27 2018-01-15 메르츠 파마 게엠베하 운트 코. 카가아 신경독 폴리펩티드의 양 및 이들의 촉매 활성 및 단백질 분해 활성의 결정수단 및 방법
ES2616258T3 (es) * 2010-03-15 2017-06-12 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna
US20170151316A1 (en) * 2014-07-02 2017-06-01 Spherium Biomed, S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)
US10704035B2 (en) * 2015-08-27 2020-07-07 President And Fellows Of Harvard College Compositions and methods for treatment of pain
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
EP3723784A4 (en) * 2017-12-15 2022-01-12 The Medical College of Wisconsin, Inc. USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS
WO2021155427A1 (en) * 2020-02-03 2021-08-12 Snoretox Pty Ltd Composition and method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDREU ALICE ET AL: "Clostridium Neurotoxin Fragments as Potential Targeting Moieties for Liposomal Gene Delivery to the CNS", CHEMBIOCHEM, vol. 9, no. 2, 25 January 2008 (2008-01-25), pages 219 - 231 *
QAZI OMAR ET AL: "Reduction of the Ganglioside Binding Activity of the Tetanus Toxin H C Fragment Destroys Immunogenicity: Implications for Development of Novel Tetanus Vaccines", INFECTION AND IMMUNITY, vol. 74, no. 8, 2006, p 4884 - 4891. *
ROSSETTO O ET AL: "Active-site mutagenesis of tetanus neurotoxin implicates TYR-375 and GLU-271 in metalloproteolytic activity", TOXICON, ELMSFORD, NY, US, vol. 39, no. 8, 1 August 2001 (2001-08-01), pages 1151 - 1159. *

Also Published As

Publication number Publication date
CA3108079C (en) 2023-10-10
EP3830110A1 (en) 2021-06-09
NZ772266A (en) 2022-09-30
JP2021533201A (ja) 2021-12-02
CA3108079A1 (en) 2020-02-06
US20210353724A1 (en) 2021-11-18
JP2024014975A (ja) 2024-02-01
WO2020024002A1 (en) 2020-02-06
KR20210040407A (ko) 2021-04-13
SG11202100646SA (en) 2021-02-25
MX2021001181A (es) 2021-04-19
NZ789962A (en) 2025-07-25
BR112021001520A2 (pt) 2021-04-20
CN112638937B (zh) 2025-06-17
EP4134133A1 (en) 2023-02-15
JP7786745B2 (ja) 2025-12-16
EP3830110A4 (en) 2022-03-02
AU2019315327A1 (en) 2021-02-11
CN120661638A (zh) 2025-09-19
CN112638937A (zh) 2021-04-09
JP2026026159A (ja) 2026-02-16
CA3167665A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
JP3755773B2 (ja) 変異型ｒドメインを有するジフテリア毒素ワクチン
JP3523879B2 (ja) 輸送タンパク質用クロストリジウム属細菌毒素の修飾
KR100594787B1 (ko) 경구용 백신 및 치료제의 전신 전달용 조성물 및 방법
KR20030033000A (ko) 류신계 모체 및 클로스트리디움계 신경독
WO2003000193A2 (en) Covalent coupling of botulinum toxin with polyethylene glycol
JP2002531064A (ja) 強化ワクチン
JP2026026159A (ja) Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療
US5695956A (en) Clostridium perfingens type a enterotoxin toxoid and methods of preparation and use as a vaccine and therapeutic agent
US20230057367A1 (en) Composition and method
Ismail et al. Preparation of a novel antivenom against Atractaspis and Walterinnesia venoms
JP2022508713A (ja) ワクチンポリペプチド組成物および方法
KR102675881B1 (ko) Pedv 스파이크 단백질 s1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
Vijayakumar et al. The use of Bacillus subtilis as a cost-effective expression system for production of Cholera Toxin B fused factor VIII epitope regions applicable for inducing oral immune tolerance
CN119462855B (zh) 一种GnRH核酸疫苗
DE69018141T2 (de) GRF-Peptide.
WO1998001754A1 (en) Novel proteins within the type e botulinum neurotoxin complex
EA048316B1 (ru) Ковалентные конъюгаты рецептор-связывающего домена sars-cov-2 и белка-носителя и содержащие их вакцинные композиции
WO2003012117A1 (en) Dna vaccine
JPH10120591A (ja) 免疫寛容誘導剤
Shtevi Design, expression, and testing of a bivalent subunit botulism vaccine for use in cattle
CZ20001399A3 (cs) Prostředky a způsoby pro systémové podání orálních vakcín a terapeutických činidel
JP2004041084A (ja) ヘリコバクター・ピロリ菌に対するワクチン用ペプチド、それをコードする遺伝子、その遺伝子が導入された形質転換体、及びそれらの利用方法
MXPA00003799A (en) Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
MXPA00011752A (en) Synthetic somatostatin immunogen for growth promotion in farm animals

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)